Coherus: TAGMO Early Data Points to Biomarker-Driven Strategy, LOQTORZI Holds the Commercial Line

Q2 2026 reveals initial TIRI-enriched clinical signals in head & neck cancer while LOQTORZI delivers record patient starts and a potential dosing upside.

CHRS · Earnings Call · 2026-08-05

A Focused Pivot Toward Immune Resistance Readouts

Coherus Oncology's Q2 2026 earnings call was framed by CEO Dennis Lanfear as “an exciting period of initial clinical data generation and readouts” — Dennis Lanfear, Chief Executive Officer · 2026-08-05 — a deliberate shift from the biosimilar legacy toward a pure-play immunotherapy pipeline. The most striking development is the emergence of a novel biomarker, the TIRI score (tumor immune regulatory index), which early data suggest may enrich for clinical benefit from tagmokitug (TAGMO), its CCR8-targeting Treg depleter. Chief Medical Officer Rosh Dias reported that among a subset of PD-1-resistant head and neck squamous cell carcinoma patients, “we're seeing greater activity in patients who are HPV positive” — Rosh Dias, Chief Medical Officer · 2026-08-05 and those with a higher TIRI score. This is early, immature, and retrospective, but it ties directly to the company's stated emphasis on immune context as the key to unlocking durable responses — a theme that has been building across quarters and now has tangible data to anchor it. The scientific narrative is intentional: TAGMO is positioned not as a response-rate agent but as a "horizontal durability layer" that depletes immunosuppressive Tregs. As Dias noted, the ultimate measure is the tail of the survival curve, echoing prior calls where he insisted that “the real benefit of IO has been in extending that tail.” — Rosh Dias, Chief Medical Officer · 2026-05-11 With the TAGMO head and neck cohort fully enrolled and a planned October disclosure, the company is betting that biomarker-defined subgroups will provide a clearer path to registration than broad unselected populations. The October data will be scrutinized not just for ORR but for clinical benefit rate, duration, and biomarker correlations — exactly the framework laid out in earlier calls.

LOQTORZI Commercial Momentum and a Hidden Lever

On the commercial side, LOQTORZI continues to execute. Q2 net sales reached $13.6 million, a 15% quarter-over-quarter increase, with the NPC patient base showing record new patient starts since launch. Chief Commercial Officer Sameer Goregaoker highlighted that duration of therapy is gradually improving, and he revealed a new opportunity: “some physicians might not be dosing for the indication” — Sameer Goregaoker, Chief Commercial Officer · 2026-08-05 — specifically, using Q3-week dosing when the label calls for Q2-week dosing in later lines. This is classic commercial headroom: correcting misdosing could add meaningful revenue without any incremental share growth. The company also reiterated its long-term targets of $15M quarterly in 2026, $30M in 2027, and peak share by 2028.

we exited the quarter with renewed momentum and strong execution. We remain confident that LOQTORZI is well positioned to achieve a $15 million quarter in 2026, a $30 million quarter in 2027 and a peak market share quarter by 2028.
Sameer Goregaoker, Chief Commercial Officer · 2026-08-05

This commercial strength is critical because the company's cash runway is tight. Cash and investments stood at $105.3 million at quarter end, down from $167 million in Q1, largely due to $39 million in TSA obligations. CFO Bryan McMichael confirmed that the first milestone earn-out from the UDENYCA divestiture was not achieved in Q2 but remains eligible. The company is deliberately managing its balance sheet to be funded through key data readouts — a delicate balance that makes the October TAGMO data even more consequential.

Financial Discipline and the Road Ahead

The financial trajectory shows a company that has cut costs sharply while commercial revenue grows. R&D expense fell to $21.4 million in Q2 (from $26.3 million a year prior), and SG&A has declined for six consecutive quarters. R&D from continuing operations is now running at roughly 2.4x LOQTORZI revenue, down from over 5x in 2024, but the absolute burn still outpaces revenue by a wide margin. The company's gross margin remains healthy at ~69%, but operating losses persist at -$37M per quarter, underscoring the importance of both pipeline success and commercial scaling. Prior calls emphasized that the company would look at "totality of evidence" rather than single endpoints. That commitment remains, but the new biomarker angle adds a layer of precision. As Dias said in March, “we are not just looking at ORR alone... durability is important, safety is important, and overall clinical benefit rate is important.” — Rosh Dias, Unknown (likely clinical development or medical officer) · 2026-03-09 The coming months will test whether TIRI can become a credible enrichment factor, potentially opening a regulatory path for a drug that many had written off. The market is not yet celebrating: the stock is down 15.5% in the last 90 days and still trades near multi-year lows. But the narrative is shifting from a generic CCR8 story to one with a specific, biomarker-driven strategy. If the October data hold up — showing not only responses but also a clear TIRI/HPV signature — Coherus could redefine its trajectory. If not, the cash runway and commercial discipline offer a buffer, but the clock is ticking. This is a classic binary inflection point, and today's call provided the first real glimpse of what could tip it.